Filing Flows › Integer Holdings (ITGR) › Q2 2026 › vs Q1 2026
Integer Holdings (ITGR) Q2 2026 vs Q1 2026 (quarter over quarter)
Integer Holdings's revenue rose $24.5M (+6%) from $440M in Q1 2026 to $464M in Q2 2026. The biggest changes: Cardio & Vascular +$18.6M (+7%); Cardiac Rhythm Management & Neuromodulation +$5.4M (+3%); Other Markets +$507K (+5%). Gross margin 24.3% against 24.9% (-0.6 pts).
Integer Holdings, Q2 2026: revenue $464M (-3% year over year), operating margin 7.4%, net earnings $23.6M, operating cash flow $59.7M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Gross margin | 24.3% | 24.9% | -0.6 pts |
| Operating margin | 7.4% | 7.2% | +0.2 pts |
| Net margin | 5.1% | 3.8% | +1.3 pts |
| Free cash flow margin | 8.0% | 0.2% | +7.8 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Cardio & Vascular | $280M | $262M | $18.6M | +7% |
| Cardiac Rhythm Management & Neuromodulation | $174M | $168M | $5.4M | +3% |
| Other Markets | $10.1M | $9.6M | $507K | +5% |
| Revenue | $464M | $440M | $24.5M | +6% |
| Gross profit | $113M | $110M | $3.3M | +3% |
| Cost of revenue | $351M | $330M | $21.2M | +6% |
| Operating profit | $34.5M | $31.9M | $2.7M | +8% |
| Operating expenses | $78.4M | $77.7M | $688K | +0.9% |
| Pre-tax earnings | $23.3M | $20.4M | $2.9M | +14% |
| Other expense, net | $11.2M | $11.5M | −$281K | -2% |
| Research & development | $11.3M | $16.2M | −$5.0M | -31% |
| SG&A | $57.7M | $58.7M | −$1.0M | -2% |
| Other operating costs | $9.4M | $2.8M | $6.7M | +240% |
| Income tax benefit | $314K | −$3.8M | $4.2M | — |
| Net earnings | $23.6M | $16.5M | $7.1M | +43% |
| Depreciation & amortization | $34.5M | $35.0M | −$473K | -1% |
| Share-based compensation | $5.4M | $6.7M | −$1.3M | -19% |
| Working capital & other | $3.8M | $33.5M | −$29.7M | -89% |
| Operating cash flow | $59.7M | $24.7M | $35.0M | +142% |
| Free cash flow (OCF − capex) | $37.0M | $737K | $36.3M | 50× |
| Capital expenditures | $22.7M | $24.0M | −$1.3M | -5% |
Questions
How much did Integer Holdings's revenue grow quarter over quarter in Q2 2026?
Integer Holdings's revenue rose $24.5M (+6%) from $440M in Q1 2026 to $464M in Q2 2026.
What drove Integer Holdings's revenue change in Q2 2026?
Cardio & Vascular +$18.6M (+7%); Cardiac Rhythm Management & Neuromodulation +$5.4M (+3%); Other Markets +$507K (+5%).